Eli Lilly and Company (NYSE:LLY) Bank of America Securities 2023 Healthcare Conference May 10, 2023 1:00 PM ET Company Participants Patrik Jonsson - Executive Vice President, President-Lilly Immunology, President-Lilly USA & Chief Customer Officer Conference Call Participants Geoff Meacham - BofA Geoff Meacham Okay. Welcome to the second day of the BofA Healthcare Conference. My name is Geoff Meacham and I'm the Senior Biopharma Analyst here at BofA. We're thrilled today to have Eli Lilly. And speaking on b ...

• • • • • • • • • • • • ...

Eli Lilly and Company (NYSE:LLY) Q1 2023 Earnings Conference Call April 27, 2023 10:00 AM ET Company Participants Joe Fletcher - Senior Vice President of Investor Relations David Ricks - Chairman & Chief Executive Officer Anat Ashkenazi - Chief Financial Officer Daniel Skovronsky - Chief Scientific & Medical Officer Anne White - President, Lilly Neuroscience Ilya Yuffa - President, Lilly International Lilly Jake Van Naarden - CEO of Loxo at Lilly Mike Mason - President, Lilly Diabetes Patrik Jonsson - Presi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 COMMISSION FILE NUMBER 001-6351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and zip ...

Corporate Presentation Forward Looking Statements These slides contain forward-looking statements and information relating to DICE Therapeutics, Inc. within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on forward-looking statements, as these statements are based upon our current expectations, forecasts, and assumptions and are subject to significant risks and uncertainties. Any statements contain ...

Eli Lilly and Company (NYSE:LLY) Cowen's 43rd Annual Health Care Conference March 6, 2023 1:30 PM ET Company Participants Mike Mason - President of Lilly Diabetes Conference Call Participants Unidentified Company Representative [Call Starts Abruptly] at the Cowen Conference again this year. Representing the company is Mike Mason, who is President of Lilly Diabetes. So Mike, thank you for making the journey. Lots to cover, obviously, an incredibly exciting business within Lilly. And so let's start right out. ...

United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 Commission file number 001-06351 ELI LILLY AND COMPANY (Exact name of Registrant as specified in its charter) Indiana 35-0470950 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Lilly Corporate Center, Indianapolis, Indiana 46285 (Address and zip cod ...

Eli Lilly and Co (NYSE:LLY) SVB Securities Global Biopharma Conference February 16, 2023 12:00 PM ET Company Participants Ilya Yuffa - SVP & President, Lilly International Conference Call Participants David Risinger - SVB Securities David Risinger Great. Good morning, everybody. So thanks very much for joining us for this next session with Eli Lilly. On behalf of SVB Securities, it's very much my pleasure to welcome Ilya Yuffa, who is Executive Vice President and President of Lilly International Operations. ...

Eli Lilly and Company (NYSE:LLY) Q4 2022 Earnings Conference Call February 2, 2023 10:00 AM ET Company Participants Joe Fletcher - Senior Vice President of Investor Relations Dave Ricks - Chairman & Chief Executive Officer Anat Ashkenazi - Chief Financial Officer Dan Skovronsky - Chief Scientific & Medical Officer Anne White - President, Lilly Neuroscience Ilya Yuffa - President, Lilly International Lilly Mike Mason - President, Lilly Diabetes Patrik Jonsson - President of Lilly Immunology & Lilly USA Conf ...

Lilly Q4 2022 Earnings Call February 2, 2023 AGENDA INTRODUCTION AND KEY RECENT EVENTS Dave Ricks, Chair and Chief Executive Officer 04 2022 FINANCIAL RESULTS Anat Ashkenazi, Chief Financial Officer R&D UPDATE Dan Skovronsky, M.D., Ph.D., Chief Scientific and Medical Officer CLOSING REMARKS Dave Ricks, Chair and Chief Executive Officer QUESTION AND ANSWER SESSION Not for promotional use 2022 Q4 EARNINGS 2 SAFE HARBOR PROVISION This presentation contains forward-looking statements that are based on managemen ...